Attreyi Mukherjee
Director/Miembro de la Junta en Impetis Biosciences Ltd. .
Perfil
Attreyi Mukherjee currently works as a Director at Impetis Biosciences Ltd.
Cargos activos de Attreyi Mukherjee
Empresas | Cargo | Inicio |
---|---|---|
Impetis Biosciences Ltd.
Impetis Biosciences Ltd. BiotechnologyHealth Technology Part of Tata Chemicals Ltd., Impetis Biosciences Ltd. is an IP focused drug discovery and licensing company founded in 2017. Impetis is headquartered in Mumbai, India, and seeks to license its assets to pharma companies for further development. The Indian company has developed therapeutic assets for autoimmune and inflammatory diseases, immuno-oncology, and Nonalcoholic steatohepatitis (NASH). The company's therapeutic assets include Receptor Activator (GRA), Bruton's Tyrosine Kinase Inhibitors (BTKi), ROR?t Inhibitor Program, GPR91 antagonists, and Adenosine receptor antagonists. The Board of Directors includes Mr. KRS Jamwal (Executive Director, Tata Industries), Mr. S. Sriram (CFO and Company Secretary, Tata Industries), and Attreyi Mukherjee (Senior Corporate Counsel, Tata Industries Ltd. & Director, Impetis Biosciences). | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Impetis Biosciences Ltd.
Impetis Biosciences Ltd. BiotechnologyHealth Technology Part of Tata Chemicals Ltd., Impetis Biosciences Ltd. is an IP focused drug discovery and licensing company founded in 2017. Impetis is headquartered in Mumbai, India, and seeks to license its assets to pharma companies for further development. The Indian company has developed therapeutic assets for autoimmune and inflammatory diseases, immuno-oncology, and Nonalcoholic steatohepatitis (NASH). The company's therapeutic assets include Receptor Activator (GRA), Bruton's Tyrosine Kinase Inhibitors (BTKi), ROR?t Inhibitor Program, GPR91 antagonists, and Adenosine receptor antagonists. The Board of Directors includes Mr. KRS Jamwal (Executive Director, Tata Industries), Mr. S. Sriram (CFO and Company Secretary, Tata Industries), and Attreyi Mukherjee (Senior Corporate Counsel, Tata Industries Ltd. & Director, Impetis Biosciences). | Health Technology |
- Bolsa de valores
- Insiders
- Attreyi Mukherjee